Takeda Ends Development of Diabetes Drug

NEW YORK (AP) -- Japanese drugmaker Takeda is ending research on its type 2 diabetes drug fasiglifam because of concerns about its effects on patients' livers.

Takeda said Thursday that it has evaluated data from clinical trials of the drug and consulted with experts, concluding that the benefits of treating patients with fasiglifam don't outweigh the risks. The company was conducting late-stage studies of the drug.

Takeda Pharmaceutical Co. said it will continue studying potential treatment for diabetes.

link


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2777389, ~/Articles/ArticleHandler.aspx, 10/1/2014 12:14:06 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement